|
1.
|
Polyak K: On the birth of breast cancer.
Biochim Biophys Acta. 1552:1–13. 2001.PubMed/NCBI
|
|
2.
|
Goss PE: Breast cancer prevention –
clinical trials strategies involving aromatase inhibitors. J
Steroid Biochem Mol Biol. 86:487–493. 2003.
|
|
3.
|
Dong X, Han ZC and Yang R: Angiogenesis
and antiangiogenic therapy in hematologic malignancies. Crit Rev
Oncol Hematol. 62:105–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Schneider BP and Miller KD: Angiogenesis
of breast cancer. J Clin Oncol. 23:1782–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Nishida N, Yaho H, Nishida T, Kamura T and
Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag.
2:213–219. 2006. View Article : Google Scholar
|
|
6.
|
Pang R and Ronnie TP: Angiogenesis and
antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett.
242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Eichhorn ME, Kleespies A, Angele MK, et
al: Angiogenesis in cancer: molecular mechanisms clinical impact.
Langenbecks Arch Surg. 392:371–379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
D’Amato RJ, Loughnan MS, Flynn E, et al:
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci
USA. 91:4082–4085. 1994.
|
|
9.
|
Kenyon BM, Browne F and D’Amato RJ:
Effects of thalidomide and related metabolites in a mouse corneal
model of neovascularization. Exp Eye Res. 64:971–978. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Bauer KS, Dixon SC and Figg WD: Inhibition
of angiogenesis by thalidomide requires metabolic activation, which
is speciesdependent. Biochem Pharmacol. 55:1827–1834. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Gasparini G, Longo R, Fanelli M, et al:
Combination of antiangiogenic therapy with other anticancer
therapies: results, challenges, and open questions. J Clin Oncol.
23:1295–1311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Adamowicz K, Marczewska M and Jassem J:
Combining systemic therapies with radiation in breast cancer.
Cancer Treat Rev. 35:409–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Nieder C, Wiedenmann N, Andratschke N, et
al: Current status of angiogenesis inhibitors combined with
radiation therapy. Cancer Treat Rev. 32:348–364. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Harrison L and Blackwell K: Hypoxia and
anemia: factors in decreased sensitivity to radiation therapy and
chemotherapy? Oncologist. 9:31–40. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Mravec B, Gidron Y and Hulin I:
Neurobiology of cancer: interactions between nervous, endocrine and
immune systems as a base for monitoring and modulating the
tumorigenesis by the brain. Sem Cancer Biol. 18:150–163. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Sumner SC, Gallagher KS, Davis DG, et al:
Conformational analysis of the tachykinins in solution: substance P
and physalaemin. J Biomol Struct Dyn. 8:687–707. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Carter MS and Krause JE: Structure,
expression and some regulatory mechanisms of the rat
preprotachykinin gene encoding substance P, neurokinin A,
neuropeptide K and neuropeptide gamma. J Neurosci. 10:2203–2214.
1990.
|
|
18.
|
Erin N and Ulusoy O: Differentiation of
neuronal from nonneuronal Substance P. Regul Pept. 152:108–113.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Erin N and Clawson GA: Parameters
affecting substance P measurement in heart, lung, and skin.
Biotechniques. 37:232–239. 2004.PubMed/NCBI
|
|
20.
|
Singh D, Joshi DD, Hameed M, et al:
Increased expression of preprotachykinin-I and neurokinin receptors
in human breast cancer cells: implications for bone marrow
metastasis. Proc Natl Acad Sci USA. 97:388–393. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Verheul HM, Pangigrahy D, Yuan J, et al:
Combination oral antiangiogenic therapy with thalidomide and
sulindac inhibits tumor growth in rabbits. Br J Cancer. 79:114–118.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kotoh T, Dhar DK, Masunaga R, et al:
Antiangiogenic therapy of human esophageal cancers with thalidomide
in nude mice. Surgery. 125:536–544. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
McMeekin DS, Sill MW, Benbrook D, et al: A
phase II trial of thalidomide in patients with refractory
endometrial cancer and correlation with angiogenesis biomarkers: a
Gynecologic Oncology Group study. Gynecol Oncol. 105:508–516. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Itasaka S, Komaki R, Herbst RS, et al:
Endostatin improves radioresponse and blocks tumor
revascularization after radiation therapy for A431 xenografts in
mice. Int J Radiat Oncol Biol Phys. 67:870–878. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Vala IS, Martins LR, Imaizumi N, et al:
Low doses of ionizing radiation promote tumor growth and metastasis
by enhancing angiogenesis. PLoS One. 5:e112222010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Chan LW and Camphausen K: Angiogenic tumor
markers, anti-angiogenic agents and radiation therapy. Expert Rev
Anticancer Ther. 3:357–366. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Esteban F, Gonzalez-Moles MA, Castro D, et
al: Expression of substance P and neurokinin-1-receptor in
laryngeal cancer: linking chronic inflammation to cancer promotion
and progression. Histopathology. 54:258–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Aalto Y, Forsgren S, Kjörell U, Bergh J,
Franzén L and Henriksson R: Enhanced expression of neuropeptides in
human breast cancer cell lines following irradiation. Peptides.
19(2): 231–239. 1998. View Article : Google Scholar : PubMed/NCBI
|
